Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

August 4-5, 2017

Philadelphia, PA

Scientific Agenda

Friday, August 4, 2017

9:30 am

Welcome and introduction
Srdan Verstovsek, MD, PhD and Rami Komrokji, MD

Session I: Biology of Myeloproliferative Neoplasms and Myelodysplastic Syndromes

9:35 am

Pre-session audience survey

9:45 am

Myelodysplastic syndromes: Genomic landscape
David A. Sallman, MD

10:05 am

Advances in understanding of MDS microenvironment
Christopher B. Benton, MD

10:25 am

Role of immune system in MDS pathogenesis
P.K. Epling-Burnette, MD

10:45 am

Break

11:15 am

New mouse models of MPN
Ann Mullally, MD

11:35 am

Mechanisms of bone marrow fibrosis in myelofibrosis
Zeev Estrov, MD

11:55 am

Post-session audience survey

12:10 pm

Panel discussion and questions

12:35 pm

Lunch symposium: Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care

Session II: Clinical Aspects of Myeloproliferative Neoplasms (I)

2:35 pm

Pre-session audience survey

2:40 pm

Biology and therapy of advanced mastocytosis
Celalettin Ustun, MD

3:00 pm

Topical challenges in the management of ET
Laura C. Michaelis, MD

3:20 pm

Diagnostic and treatment enigmas in PV
Brady Lee Stein, MD, MHS

3:40 pm

Break

4:10 pm

Is there still a role for splenectomy and splenic radiation in management of MPN?
Elizabeth O. Hexner, MD, MSTR

4:30 pm

My view on current and future use of JAK inhibitors for ET, PV, and MF
John Mascarenhas, MD

4:50 pm

Post-session audience survey

4:55 pm

Panel discussion and questions

5:10 pm

Take-home points

5:15 pm

Adjourn

 

Saturday, August 5, 2017

9:30 am

Welcome to Day 2
Srdan Verstovsek, MD, PhD and Rami Komrokji, MD

Session III: Clinical Aspects of Myelodysplastic Syndromes

9:35 am

Pre-session audience survey

9:40 am

CHIP & ICUS: What do we know and what do we need to do?
David P. Steensma, MD

10:00 am

My approach to MDS management
Rami Komrokji, MD

10:20 am

Break

10:50 am

Iron chelation therapy for MDS
Amer Zeidan, MBBS, MHS

11:10 am

Optimal use of lenalidomide as therapy for MDS
Aaron T. Gerds, MD, MS

11:30 am

New opportunities in experimental therapeutics in MDS
Amy E. DeZern, MD, MHS

11:50 am

Post-session audience survey

11:55 am

Panel discussion and questions

12:10 pm

Lunch

Session IV: Clinical Aspects of Myeloproliferative Neoplasms (II)

2:10 pm

Pre-session audience survey

2:20 pm

MF marrow morphology: Key takeaways from WHO 2016 diagnostic update
Carlos E. Bueso-Ramos, MD, PhD

2:40 pm

What is new in thrombosis in MPN
Craig M. Kessler, MD

3:00 pm

Therapeutic insights in clonal evolution of MPN to accelerated or blastic phase
Raajit K. Rampal, MD, PhD

3:20 pm

Break

3:50 pm

My approach to MF management
Olatoyosi Odenike, MD

4:15 pm

Experimental therapeutics in MPN: Where is the field going?
Srdan Verstovsek, MD, PhD

4:30 pm

Post-audience survey

4:35 pm

Panel discussion and questions

4:50 pm

Take-home points

5:00 pm

Adjourn